Fraunhofer Institute of Toxicology and Experimental Medicine, Hannover, Germany.
Institute of Natural Sciences, Massey University, Auckland, New Zealand.
PLoS One. 2013 Dec 20;8(12):e83295. doi: 10.1371/journal.pone.0083295. eCollection 2013.
Germline mutations in cardiac-specific transcription factor genes have been associated with congenital heart disease (CHD) and the homeodomain transcription factor NKX2-5 is an important member of this group. Indeed, more than 40 heterozygous NKX2-5 germline mutations have been observed in individuals with CHD, and these are spread along the coding region, with many shown to impact protein function. In pursuit of understanding causes of CHD, we analyzed n = 49 cardiac biopsies from 28 patients and identified by direct sequencing two nonsynonymous NKX2-5 alterations affecting alanine 119, namely c.356C>A (p.A119E) and c.355G>T, (p.A119S), in patients with AVSD and HLHS, respectively. In functional assays, a significant reduction in transcriptional activities could be determined for the NKX2-5 variants. Importantly, in one family the mother, besides p.A119E, carried a synonymous mutant allele in the homeodomain (c.543G>A, p.Q181), and a synonymous dbSNP (c.63A>G, p.E21) in the transactivation domain of the protein, that were transmitted to the CHD daughter. The presence of these variants in-cis with the p.A119E mutation led to a further reduction in transcriptional activities. Such difference in activity may be in part related to reduced protein expression for the double variant c.356C>A and c.543G>A. We propose changes in mRNA stability and folding, due to a silent mutation and a dbSNP in the NKX2-5 coding region to contribute to the functional defect. Although the clinical significance of the NKX2-5 haplotype identified in the CHD patients remains to be ascertained, we provide evidence of an interaction of a dbSNP, with synonymous and nonsynonymous mutations to negatively impact NKX2-5 transcriptional activity.
心脏特异性转录因子基因的种系突变与先天性心脏病(CHD)有关,同源域转录因子 NKX2-5 是该组的重要成员。事实上,在患有 CHD 的个体中已经观察到超过 40 种杂合性 NKX2-5 种系突变,并且这些突变分布在编码区域,其中许多突变影响蛋白质功能。为了了解 CHD 的原因,我们分析了 28 名患者的 49 份心脏活检,并通过直接测序鉴定出两种非同义 NKX2-5 改变,分别影响丙氨酸 119,即 c.356C>A(p.A119E)和 c.355G>T(p.A119S),在房室隔缺损和 HLHS 患者中。在功能测定中,可确定 NKX2-5 变体的转录活性显著降低。重要的是,在一个家庭中,除了 p.A119E 外,母亲还携带同源域中的同义突变等位基因(c.543G>A,p.Q181),以及蛋白质的反式激活域中的同义 dbSNP(c.63A>G,p.E21),这些突变基因都传递给了 CHD 女儿。这些变体与 p.A119E 突变的顺式存在导致转录活性进一步降低。这种活性差异可能部分与双重变体 c.356C>A 和 c.543G>A 的蛋白质表达减少有关。我们提出由于 NKX2-5 编码区域中的沉默突变和 dbSNP,导致 mRNA 稳定性和折叠发生变化,从而导致功能缺陷。尽管在 CHD 患者中鉴定的 NKX2-5 单倍型的临床意义仍有待确定,但我们提供了证据表明 dbSNP 与同义和非同义突变相互作用,对 NKX2-5 转录活性产生负面影响。